Table 3 Efficacy outcomes by tumor type
|  | Platinum-sensitive OC (n = 10) | Platinum-resistant OC (n = 17) | TNBC (n = 22) | Total (n = 52)a |
|---|---|---|---|---|
Best overall response per RECIST v1.1, n (%) | ||||
 CR | 4 (40.0%) | 1 (5.9%) | 0 | 5 (9.6%) |
 PR | 4 (40.0%) | 5 (29.4%) | 5 (22.7%) | 14 (26.9%) |
 SD | 1 (10.0%) | 7 (41.2%) | 7 (31.8%) | 15 (28.8%) |
 PD | 1 (10.0%) | 4 (23.5%) | 9 (40.9%) | 17 (32.7%) |
 NE | 0 | 0 | 1 (4.5%) | 1 (1.9%) |
Confirmed ORR, % (95% CI) | 80.0 (44.4–97.5) | 35.3 (14.2–61.7) | 22.7 (7.8–45.4) | 36.5 (23.6–51.0) |
DCR, % (95% CI) | 90.0 (55.5–99.7) | 76.5 (50.1–93.2) | 54.5 (32.2–75.6) | 65.4 (50.9–78.0) |
Median DoR (95% CI), months | 9.3 (7.4-NR) | 18.4 (12.0-NR) | 4.5 (3.7-NR) | 11.1 (7.4–16.6) |
CA-125 response, % (95% CI)b | 100 (47.8–100) | 42.9 (17.7–71.1) | - | 50.0 (28.2–71.8) |
Median PFS (95% CI), months | 12.1 (1.9-NR) | 5.8 (2.1–18.5) | 3.8 (2.0–5.7) | 5.7 (3.5–6.7) |
Median OS (95% CI), months | NR (20.4-NR) | 25.5 (14.9-NR) | 10.7 (7.5-NR) | 21.1 (14.9–33.9) |